[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-438553-105":59,"doc-detail-438553-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dexamethasone-loaded-lipid-polymeric-nanoparticles-to-improve-therapy-for-cisplatin-induced-sensorineural-hearing-loss","Dexamethasone-loaded lipid-polymeric nanoparticles to improve therapy for cisplatin-induced sensorineural hearing loss","","Sensorineural hearing loss (SNHL) caused by ototoxic drugs such as cisplatin is difficult to treat because damage is largely irreversible. Dexamethasone can protect against SNHL but is limited by systemic adverse effects and poor inner-ear bioavailability with conventional administration. This work develops dexamethasone-loaded lipid-polymeric nanoparticles (LPNs) using stearic acid and PLGA via double-emulsion solvent evaporation. The LPNs show favorable size, PDI, and zeta potential, sustained release over 72 h, improved cytoprotection in HEI-OC1 cells, and enhanced cochlear drug distribution in a cisplatin mouse model. Results indicate reduced ABR thresholds after intratympanic injection and support targeted, sustained delivery potential for clinical translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dexamethasone-loaded-lipid-polymeric-nanoparticles-to-improve-therapy-for-cisplatin-induced-sensorineural-hearing-loss/438553/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dexamethasone-loaded-lipid-polymeric-nanoparticles-to-improve-therapy-for-cisplatin-induced-sensorineural-hearing-loss/438553.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cisplatin-induced sensorineural hearing loss difficult to treat?","Question",{"text":112,"@type":113},"It is largely irreversible damage to cochlear hair cells or the auditory nerve, and cisplatin causes permanent SNHL in many cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What problem does conventional dexamethasone therapy have for SNHL?",{"text":117,"@type":113},"Systemic dexamethasone can trigger adverse effects, and intratympanic administration still suffers from drug escape, limited inner-ear penetration, and reduced bioavailability due to poor water solubility.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the developed lipid-polymeric nanoparticles improve therapy in the study?",{"text":121,"@type":113},"The LPNs provide sustained dexamethasone release, better cytoprotection against cisplatin toxicity in vitro, enhanced cochlear drug distribution, and significantly reduced ABR thresholds after intratympanic injection.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},438553,1790766627,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Nanoscale Advances  \nPAPER  \nCite this: DOI: 10 .1039/d5na00419e  \nReceived 30th April 2025  \nAccepted 15th October 2025 DOI: 10.1039/d5na00419e[rsc.li/nanoscale-advances](rsc.li/nanoscale-advances)  \nDexamethasone-loaded lipid-polymeric nanoparticles to improve therapy for cisplatininduced sensorineural hearing loss  \nWang Qi, † Huang Qiling,† Li Liling,† Li Zhicheng, Li Peng* and Zeng Xiangli*  \nSensorineural hearing loss (SNHL), caused by ototoxic drugs like cisplatin, poses significant challenges due to its irreversible nature. Dexamethasone, a potent corticosteroid, is commonly used to mitigate SNHL butsuffers from systemic side effects and poor inner ear bioavailability when administered conventionally. This study explores the potential of dexamethasone-loaded lipid-polymeric nanoparticles (LPNs) to enhance drug delivery efficiency and therapeutic outcomes. The LPNs were fabricated using stearic acid and poly (lactic-co-glycolic acid) (PLGA) via a double emulsion solvent evaporation method, combining the biocompatibility of lipid nanoparticles with the sustained-release properties of polymeric nanoparticles. Characterization revealed optimal particle size (∼150 nm by SEM and ∼380 nm by LDE), polydispersity index (PDI 0 . 233), and z-potential ( −21. 9 mV), ensuring colloidal stability and cellular uptake. In vitro studies demonstrated sustained dexamethasone release over 72 hours, with 55.56% released within 4 hours. HEI-OC1 cell viability assays confirmed the LPNs' cytocompatibility and superior protection against cisplatin-induced cytotoxicity compared to raw dexamethasone. In vivo experiments ina cisplatin-induced ototoxicity mouse model showed enhanced cochlear drug distribution, peaking at 24 hours, and significantly reduced auditory brainstem response (ABR) thresholds at 16 kHz and 32 kHz post-intratympanic injection. These findings highlight the LPNs' potential as a targeted, sustained-release delivery system for treating SNHL, offering improved efficacy and reduced systemic exposure. This study provides a foundation for clinical translation of LPN-based therapies in otoprotection.  \n1. Introduction  \nSensorineural hearing loss (SNHL) is a prevalent and o􀀁en irreversible condition that impacts millions of people, affecting their quality of life. SNHL arises from damage to the hair cells of the cochlea or the auditory nerve, leading to a decline in the ability to perceive sound. Cisplatin, a widely used chemotherapeutic agent, is known to cause ototoxicity and SNHL. Cisplatin induces bilateral, permanent sensorineural hearing loss in a staggering 80% of cancer patients, with many also experiencing the distressing symptom of tinnitus.1 Approximately 500 000 new patients each year were recorded2,3 and dexamethasone is a standard treatment with proven protective effects against cisplatin-induced ototoxicity.4 Dexamethasone is a potent corticosteroid with anti-in􀀁ammatory and immunosuppressive properties.5,6 It has been widely recognized for its potential to mitigate in􀀁ammation and protect auditory cells,  \nDepartment of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Tianhe District, 510000 Guangzhou, Guangdong, China. E-mail: [zxiangl@mail.sysu.edu.cn](zxiangl@mail.sysu.edu.cn); lipeng25@mail. [sysu.edu.cn](sysu.edu.cn)  \n† These authors contributed equally to this work.  \n© 2025 The Author(s) . Published by the Royal Society of Chemistry  \nmaking it the most common medication prescribed for SNHL treatment.7  \nSystemic dexamethasone, despite its therapeutic bene􀀃ts, can lead to adverse effects such as acneiform eruptions, desquamation of the skin, osteoporosis or osteonecrosis, opportunistic infections, and suppression of the adrenal cortex. These adverse effects arise due to its high affinity for glucocorticoid receptors.8–10 Intratympanic injection is an alternative method to avoid systemic side effects associated with dexamethasone.11 However, the eustachian tube a","cbCaiuopVZw5LgKF","https://ap.wps.com/l/cbCaiuopVZw5LgKF","pdf",1367933,"English","# Introduction\n## Background on SNHL and cisplatin ototoxicity\n## Limits of conventional dexamethasone therapy\n## Rationale for dexamethasone-loaded lipid-polymeric nanoparticles\n## Related delivery approaches and remaining needs","[{\"question\":\"Why is cisplatin-induced sensorineural hearing loss difficult to treat?\",\"answer\":\"It is largely irreversible damage to cochlear hair cells or the auditory nerve, and cisplatin causes permanent SNHL in many cancer patients.\"},{\"question\":\"What problem does conventional dexamethasone therapy have for SNHL?\",\"answer\":\"Systemic dexamethasone can trigger adverse effects, and intratympanic administration still suffers from drug escape, limited inner-ear penetration, and reduced bioavailability due to poor water solubility.\"},{\"question\":\"How do the developed lipid-polymeric nanoparticles improve therapy in the study?\",\"answer\":\"The LPNs provide sustained dexamethasone release, better cytoprotection against cisplatin toxicity in vitro, enhanced cochlear drug distribution, and significantly reduced ABR thresholds after intratympanic injection.\"}]","Dexamethasone-loaded lipid-polymeric nanoparticles to improve therapy for cisplatin-induced sensorineural hearing loss | PDF",1790685695,25]